Navigation Links
Hollis-Eden Announces Name Change to Harbor BioSciences, Inc. and Ticker Symbol Change to 'HRBR'
Date:2/17/2010

SAN DIEGO, Feb. 17 /PRNewswire-FirstCall/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH), today announced that it has changed its name to Harbor BioSciences, Inc. and that its ticker symbol will change from 'HEPH' to 'HRBR' on Thursday, February 18, 2010. The company also received a new CUSIP number (41150V 103) for its common stock.

"We are pleased to begin 2010 with a targeted business strategy focused on attaining proof-of-concept data for Apoptone® in its initial indication of CRPC," stated James Frincke, Ph.D., President and Chief Executive Officer. "Our new name, Harbor BioSciences, reflects our presence in the San Diego area and acknowledges the significant contributions of our dedicated employees here."  

Apoptone (HE3235) is a novel steroid analog of a dihydrotestosterone metabolite that has been found to stimulate cell death (apoptosis) in hormone-dependent prostate tumors.  Preliminary results of the company's ongoing Phase I/IIa clinical trial with Apoptone (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC) were presented on November 16, 2009 at the Molecular Targets and Cancer Therapeutics Conference.  These data will be updated later in Q1/2010.

About Harbor BioSciences, Inc.

Harbor BioSciences is a development-stage company with two product candidates in clinical trials: Apoptone (HE3235), in the cohort expansion portion of a Phase I/IIa trial of patients with late-stage prostate cancer, and Triolex®, in a Phase IIa trial in obese type 2 diabetes mellitus patients.  The Triolex study will be completed in Q1/2010, with data expected in Q2/2010. Apoptone and Triolex represent the lead candidates from Harbor BioSciences small molecule platform based on metabolites or synthetic analogs of endogenous steroid hormones.  For more information on Harbor BioSciences please visit www.harborbiosciences.com.

This press release contains forward-looking statements within the meaning of the federal securities laws concerning, among other things, our receiving a new ticker symbol; our focus on attaining proof-of-concept data for Apoptone in its initial indication of CRPC; the update of the data from our ongoing Phase I/IIa clinical trial with Apoptone (HE3235) for CRPC; the completion of our Triolex study in Q1/2010; and availability of data from our Triolex study in Q2/2010.   Any statement included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause our actual results to differ materially from historical results or those expressed or implied by such forward-looking statements.  Such statements are subject to certain risks and uncertainties inherent in our business, including, but not limited to: the receipt of our new ticker symbol and the timing thereof; the ability to complete preclinical and clinical trials successfully and within specified timelines, if at all; the availability of data within specified timelines; our capital needs; our ability to obtain additional funding; our ability to obtain regulatory approval for Apoptone (HE3235), Triolex (HE3286) or any other investigational drug candidate;  and other risks detailed from time to time in our filings with the Securities and Exchange Commission.  Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.  Except as required by law, we undertake no obligation to update or revise the information contained in this press release as a result of new information, future events or circumstances arising after the date of this press release.

SOURCE Harbor BioSciences, Inc.

RELATED LINKS
http://www.harborbiosciences.com

'/>"/>

SOURCE Harbor BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sunridge Announces Marketing Roll Out of PNT in the Dominican Republic
2. Soligenix Announces Issuance of Hong Kong Patent for its LPM(TM) Oral Drug Delivery Technology
3. Otix Global Announces Results for Fourth Quarter 2009
4. Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements
5. PatientSafe Solutions, Inc. Announces Management Team
6. Sequenom Announces Launch of SensiGene Fetal(XY) (Fetal Sex Determination) Test
7. CalciMedica Announces Issuance of US Patent No. 7,645,588, a Composition Patent Involving STIM1, a Key Component of the CRAC Channel
8. VetCentric Announces Partnership With Pfizer Animal Health
9. Albemarle(R) Announces Custom Manufacturing Alliance with PharmaCore(R)
10. OrbusNeich Announces First Patient Enrolled in Randomized Clinical Trial of Genous(TM) Bio-engineered R stent(TM) in China
11. Health Robotics Announces Successful Transition to new and Distinctively Superior Distribution Channels in North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 4, 2016 Mettler-Toledo International Inc. (NYSE: ... Provided below are the highlights: , Sales ... with the prior year.  Reported sales decreased 3% as ... , Net earnings per diluted share as reported ... year period.  Adjusted EPS was $4.65, an increase of ...
(Date:2/4/2016)... 4, 2016  AMRI (NASDAQ:  AMRI) today announced that ... and President of Pfizer Global Supply, has been elected to ... 2016. In addition, the Company announced that Mr. Gabe ... since 2010, has retired from the AMRI Board of Directors ... other business ventures.  William S. Marth , ...
(Date:2/4/2016)... Feb. 4, 2016 SONIFI™ Health, the ... today announced that MonteCedro, an innovative retirement community, ... System. The system provides a simple and intuitive ... through a tablet PC. ... system provides access to a wide spectrum of ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Stuart Bentkover, MD, FACS ... PicoSure. Designed to provide the most effective tattoo removal today, Dr. Bentkover is the ... , Developed by Cynosure, the PicoSure has been approved by the Food and Drug ...
(Date:2/5/2016)... ... February 05, 2016 , ... In sleep, when the defenses of the day ... feature of patients with eating disorders is significant self-criticism, and consequently these patients experience ... are regarded as maladaptive means for coping with this unease, but also leads to ...
(Date:2/5/2016)... ... February 05, 2016 , ... On June 9-10, Las Vegas ... medical education (CME) event presented by the Association for Comprehensive Care in Rare ... ACCORD, whose mission is to provide education, tools, and resources to primary care ...
(Date:2/5/2016)... ... February 05, 2016 , ... –This week, Atascadero water heater ... having a tankless water heater. To view the report, click here or ... tankless. While each has their pros and cons, the type chosen is almost entirely ...
(Date:2/4/2016)... ... February 04, 2016 , ... Dr. Carol Francis and ... February 19-21, 2016, in Southern California . The International Hypnosis Federation 2016 Conference ... professional speakers, including Clinical Psychologist and Hypnotherapist Dr. Carol Francis (topics ...
Breaking Medicine News(10 mins):